Table 1.
Demographics, tumour characteristics, and treatment of patients with DCIS
| Characteristic | Patients (n = 307) (%) | |
|---|---|---|
| Age, years | Median (range) | 52 (21–82) |
| ≤ 40 | 36 (11.7) | |
| > 40 and ≤ 60 | 201 (65.5) | |
| > 60 | 70 (22.8) | |
| Preoperative characteristics | ||
| Tumour size, cm | ≤ 2 | 155 (50.5) |
| > 2 and ≤ 5 | 124 (40.4) | |
| > 5 | 28 (9.1) | |
| Palpability | Non-palpable | 234 (76.2) |
| Palpable | 73 (23.8) | |
| Mammographic calcification | Present | 192 (62.5) |
| Absent | 115 (37.5) | |
| Ultrasonic mass | Present | 198 (64.5) |
| Absent | 109 (35.5) | |
| Tumour location | Upper-outer | 105 (34.2) |
| Upper-inner | 50 (16.3) | |
| Lower-outer | 60 (19.5) | |
| Lower-inner | 65 (21.2) | |
| Multicentric | 27 (8.8) | |
| Biopsy method | Core-needle biopsy | 174 (56.7) |
| VABB | 8 (2.6) | |
| Excisional biopsy | 125 (40.7) | |
| Postoperative characteristics | ||
| Type of breast surgery | BCS | 145 (47.2) |
| TM | 162 (52.8) | |
| Type of axillary surgery | None | 105 (34.2) |
| SLNB only | 198 (64.5) | |
| SLNB and ALND | 4 (1.3) | |
| Upstaging to invasive cancer | Yes | 59 (19.2) |
| No | 248 (80.8) | |
| Axillary lymph node metastasis | Positive | 4 (1.3) |
| Negative | 303 (98.7) | |
| Permanent size of DCIS, cm | ≤ 2 | 156 (50.8) |
| 2–5 | 124 (40.4) | |
| > 5 | 27 (8.8) | |
| Permanent T stage | pTis | 248 (80.8) |
| pT1mic | 5 (1.6) | |
| pT1a–pT1c | 51 (16.6) | |
| pT2 | 3 (1.0) | |
| Nuclear grade | Low | 67 (21.8) |
| Intermediate | 150 (48.9) | |
| High | 90 (29.3) | |
| Comedo necrosis | Present | 153 (49.8) |
| Absent | 154 (50.2) | |
| ER | Positive | 241 (78.5) |
| Negative | 66 (21.5) | |
| PR | Positive | 211 (68.7) |
| Negative | 96 (31.3) | |
| HER2 | Negative | 233 (75.9) |
| Positive | 74 (24.1) | |
| Ki-67 | Low | 181 (59.0) |
| High | 126 (41.0) | |
| Main type of DCIS | Cribriform | 125 (40.7) |
| Comedo | 145 (47.2) | |
| Solid | 37 (12.1) | |
BCS breast-conserving surgery, DCIS ductal carcinoma in situ, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor, SLNB sentinel lymph node biopsy, TM total mastectomy, VABB vacuum-assisted breast biopsy